Farallon Capital Management’s AstraZeneca AZN Stock Holding History

Farallon Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109M	Buy	574,000 +347,501	+153%	+$65.4M	0.5%	33
2026 Q1	$44.7M	Buy	+226,499	New	+$43.7M	0.23%	44
2024 Q3	–	Sell	-1,204,859	Closed	-$188M	–	167
2024 Q2	$188M	Buy	1,204,859 +475,000	+65%	+$71.5M	0.81%	38
2024 Q1	$98.9M	Sell	729,859 -1,182,287	-62%	-$157M	0.42%	44
2023 Q4	$258M	Sell	1,912,146 -1,117,631	-37%	-$145M	1.18%	28
2023 Q3	$410M	Hold	3,029,777	–	–	1.91%	16
2023 Q2	$434M	Buy	3,029,777 +96,000	+3%	+$14.1M	2.18%	12
2023 Q1	$407M	Sell	2,933,777 -4,454	-0.2%	-$599K	2.22%	12
2022 Q4	$398M	Buy	2,938,231 +145,750	+5%	+$18.3M	2.35%	10
2022 Q3	$306M	Buy	2,792,481 +477,500	+21%	+$60.6M	1.68%	15
2022 Q2	$306M	Buy	2,314,981 +526,889	+29%	+$69.1M	1.66%	17
2022 Q1	$237M	Buy	1,788,092 +835,014	+88%	+$100M	1.15%	32
2021 Q4	$111M	Buy	953,078 +786,078	+471%	+$92.5M	0.55%	46
2021 Q3	$20.1M	Buy	+167,000	New	+$19.4M	0.09%	101
2019 Q4	–	Sell	-1,187,893	Closed	-$106M	–	118
2019 Q3	$106M	Sell	1,187,893 -862,107	-42%	-$74.8M	0.8%	31
2019 Q2	$169M	Buy	2,050,000 +107,500	+6%	+$8.43M	1.1%	25
2019 Q1	$157M	Hold	1,942,500	–	–	1.18%	27
2018 Q4	$148M	Buy	1,942,500 +232,500	+14%	+$18.2M	1.08%	29
2018 Q3	$135M	Sell	1,710,000 -215,000	-11%	-$16.3M	0.8%	31
2018 Q2	$135M	Buy	1,925,000 +142,500	+8%	+$10.3M	0.83%	30
2018 Q1	$125M	Sell	1,782,500 -100,000	-5%	-$6.93M	0.86%	33
2017 Q4	$131M	Buy	1,882,500 +292,500	+18%	+$19.7M	1.06%	28
2017 Q3	$108M	Buy	1,590,000 +1,302,500	+453%	+$82.3M	0.96%	28
2017 Q2	$19.6M	Sell	287,500 -288,750	-50%	-$18.9M	0.2%	55
2017 Q1	$35.9M	Buy	576,250 +393,750	+216%	+$22.9M	0.39%	43
2016 Q4	$9.97M	Buy	+182,500	New	+$10.4M	0.11%	56

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Farallon Capital Management's AZN Position: Q2 2026 in Review

Farallon Capital Management increased its AstraZeneca (AZN) stake by 153% in Q2 2026, buying an estimated $65.4M and bringing the position to 574,000 shares worth $109M. The position accounts for 0.5% of the portfolio, ranked #33.

Farallon Capital Management first reported a position in AZN in Q4 2016 and has held it in 26 quarters since. The position peaked at $434M in Q2 2023. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Farallon Capital Management held 574,000 shares of AstraZeneca worth $109M as of Q2 2026.
Farallon Capital Management bought 347,501 AstraZeneca shares in Q2 2026, an estimated $65.4M.
AstraZeneca made up 0.5% of Farallon Capital Management's portfolio in Q2 2026, its #33 holding.
Farallon Capital Management first reported a position in AstraZeneca in Q4 2016 and has held it in 26 quarters since.
Farallon Capital Management's AstraZeneca position peaked at $434M in Q2 2023.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.